10-甲基-10H-吩噻嗪5,5-二氧化物 | 19607-01-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 中文名称: 10-甲基-10H-吩噻嗪5,5-二氧化物
• 中文别名: 10-甲基-10H-苯并噻嗪5,5-二氧化
• 英文名称: N(10)-methylphenothiazine-S,S-dioxide
• 英文别名: 10-methyl-10H-phenothiazine 5,5-dioxide；10-methyl-phenothiazine-5,5-dioxide；10-Methyl-phenothiazin-5,5-dioxid；10-Methylphenothiazine 5,5-dioxide；10-Methyl-phenothiazine 5,5-dioxyde；10-Methylphenothiazine-5.5-dioxide；10-Methyl-10H-phenothiazine 5,5-dioxide
• CAS: 19607-01-3
• 化学式: C₁₃H₁₁NO₂S
• 分子量: 245.302
• InChiKey: SSIOPLVRUPBGPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934300000

反应信息

• 作为反应物：
  描述：

  10-甲基-10H-吩噻嗪5,5-二氧化物 、 氢碘酸 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Bernthsen, Chemische Berichte, 1906, vol. 39, p. 1808

  摘要：

  DOI：
• 作为产物：
  描述：

  N-甲基吩噻嗪 在 双氧水 作用下， 生成 10-甲基-10H-吩噻嗪5,5-二氧化物
  参考文献：
  名称：

  Oxidation of 10-Acyl- and 10-Alkylphenothiazines

  摘要：

  DOI：

  10.1021/ja01117a509

文献信息

• Phenothiazines, S-Oxides, And S,S-Dioxides As Well As Phenoxazines As Emitters For Oleds
  申请人：Gessner Thomas

  公开号：US20100308714A1

  公开（公告）日：2010-12-09

  The use of phenoxazine, phenothiazine, phenothiazine S-oxide or phenothiazine S,S-dioxide derivatives as emitter substances in organic light-emitting diodes, an organic light-emitting diode comprising a light-emitting layer, the light-emitting layer comprising at least one phenoxazine, phenothiazine, phenothiazine S-oxide or phenothiazine S,S-dioxide derivative as an emitter substance, and a light-emitting layer comprising or consisting of the aforementioned phenoxazine, phenothiazine-phenothiazine, phenothiazine S-oxide or phenothiazine S,S-dioxide derivative as an emitter substance, a hole- and exciton-blocking layer comprising or consisting of the aforementioned phenoxazine derivative, phenothiazine derivative, phenothiazine S-oxide derivative or phenothiazine S,S-dioxide derivative, and a device which comprises an inventive organic light-emitting diode. The present invention further relates to specific phenothiazine S,S-dioxide derivatives, phenothiazine S-oxide derivatives and phenothiazine derivatives and production processes thereof, and to their use in organic light-emitting diodes.

  使用苯氧嗪、苯噻嗪、苯噻嗪S-氧化物或苯噻嗪S,S-二氧化物衍生物作为有机发光二极管中的发射物质，一种有机发光二极管包括一个发光层，该发光层至少包括一种苯氧嗪、苯噻嗪、苯噻嗪S-氧化物或苯噻嗪S,S-二氧化物衍生物作为发射物质，以及一个包含或由上述苯氧嗪、苯噻嗪、苯噻嗪S-氧化物或苯噻嗪S,S-二氧化物衍生物作为发射物质的发光层，一个包含或由上述苯氧嗪衍生物、苯噻嗪衍生物、苯噻嗪S-氧化物衍生物或苯噻嗪S,S-二氧化物衍生物的空穴和激子阻挡层，以及包含创新有机发光二极管的器件。本发明还涉及特定的苯噻嗪S,S-二氧化物衍生物、苯噻嗪S-氧化物衍生物和苯噻嗪衍生物及其生产工艺，以及它们在有机发光二极管中的使用。
• DOUBLE SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME
  申请人：LG CHEM, LTD.

  公开号：US20180111887A1

  公开（公告）日：2018-04-26

  The present specification relates to a double spiro structure compound and an organic light emitting device including the same.

  本说明书涉及一种双螺旋结构化合物和包括该化合物的有机发光器件。
• HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME
  申请人：LG Chem, Ltd.

  公开号：US20180037547A1

  公开（公告）日：2018-02-08

  The present specification relates to a hetero-cyclic compound and an organic light emitting device including the same.

  本规范涉及一种杂环化合物和包括该化合物的有机发光装置。
• SULFONIUM SALT, RESIST COMPOSITION, AND PATTERNING PROCESS
  申请人：Shin-Etsu Chemical Co., Ltd.

  公开号：US20180088464A1

  公开（公告）日：2018-03-29

  On use of a sulfonium salt of specific structure as PAG, acid diffusion is suppressed. A resist composition comprising the sulfonium salt forms a pattern with improved lithography properties including EL, MEF and LWR when processed by lithography.

  使用具有特定结构的磺鎵盐作为PAG时，可以抑制酸扩散。包括EL、MEF和LWR在内的改进的光刻特性的图案可以由含有该磺鎵盐的光阻组成的深紫外光刻胶处理而成。
• Organic compounds
  申请人：Damon Edson Robert

  公开号：US20070004704A1

  公开（公告）日：2007-01-04

  Compounds of the formula provide pharmacological agents which bind to Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the present invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases (IBDs), ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X.

  本发明的化合物具有以下公式，可提供与过氧化物酶体增殖物激活受体（PPARs）结合的药理剂。因此，本发明的化合物对于治疗哺乳动物中由PPAR受体活性介导的疾病是有用的。这些疾病包括失调脂质代谢、高脂血症、高胆固醇血症、动脉粥样硬化、高甘油三酯血症、心力衰竭、心肌梗死、血管疾病、心血管疾病、高血压、肥胖症、炎症、关节炎、癌症、阿尔茨海默病、皮肤疾病、呼吸系统疾病、眼部疾病、炎症性肠病（IBD）、溃疡性结肠炎和克罗恩病。本发明的化合物在哺乳动物中作为降糖药物特别有用，用于治疗和预防因受损葡萄糖耐受性、高血糖和胰岛素抵抗而引起的疾病，例如1型和2型糖尿病以及X综合症。